NoteAbsorption and efficiency of insulin after oral administration of insulin-loaded nanocapsules in diabetic rats
Section snippets
Acknowledgements
We are indebted to the Eli Lilly Company (Indianapolis, USA) for a generous supply of Humalog®. We are very grateful to Loctite Compagny (Dublin, Ireland) for the supply of Isobutylcyanoacrylate. F. Cournarie was a fellow from the CNRS and Assistance Publique des Hôpitaux de Paris.
References (7)
- et al.
Development of a new process for manufacture of polyisobutylcyanoacrylate nanocapsules
Int. J. Pharm.
(1986) - et al.
Insulin-loaded nanocapsules for oral administration: in vitro and in vivo investigation
Drug Dev. Res.
(2000) - et al.
Early appearance of in vivo insulin resistance in adult streptozotocin-injected rats
Diab. Metab.
(1989)
Cited by (38)
Advances on the formulation of proteins using nanotechnologies
2017, Journal of Drug Delivery Science and TechnologyLipid-based nanocarriers for oral peptide delivery
2016, Advanced Drug Delivery ReviewsCitation Excerpt :The stability of lipid-based drug delivery systems in simulated biological fluids may vary depending on their composition and, notably on the presence of polymer coatings protecting the lipids from degradation. For instance, the polymeric shell of NCs may offer protection from exposure to low gastric pH and enzymatic degradation [81,83,130,135,145,152–157]. In addition, the solid physical state of SLN is also expected to help to protect the encapsulated peptide [48,77,78,85,87], although potential degradation of SLNs may happen [60].
Oral delivery of therapeutic protein/peptide for diabetes-Future perspectives
2013, International Journal of PharmaceuticsCitation Excerpt :By virtue of the size of these particles, or its capability in enhancing the permeability by altering tight junctions, or by facilitating receptor mediated uptake the absorption also can be improved. Lots of literature on various oral insulin formulations which is dealing thoroughly with all aspects is extensively available (Damge et al., 1988; Cournarie et al., 2002; Kim and Peppas, 2000; Kim et al., 2005a,b; Kavimandan et al., 2006; Paul and Sharma, 2008; Sajeesh and Sharma, 2006; Rekha and Sharma, 2008a,b, 2009a,b). In this section, therefore we are focusing on those articles in which in vivo efficacy is evaluated.
Nanotechnology as a promising strategy for alternative routes of insulin delivery
2012, Methods in EnzymologyCitation Excerpt :After oral administration of PIBCA nanospheres to diabetic rats, blood glucose levels decreased from the second hour onward, over a 40 h period (Mesiha et al., 2005). In addition, Cournarie et al. (2002) only detected a significant but rapid increase in plasma insulin levels (30 min to 1 h postadministration) after oral administration of insulin-loaded PIBCA nanocapsules to diabetic rats without decrease of glycemia. According to these authors, insulin-resistance that was developed by their diabetic rats should explain these results.
Oral insulin delivery using nanoparticles based on microemulsions with different structure-types: Optimisation and in vivo evaluation
2009, European Journal of Pharmaceutical Sciences